We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Muriel M. Liberto, Ph.D. Esq.

Mintz

Results 1 to 5 of 9
Most popular |Most recent


With its Vanda Pharma and Berkheimer Memos, USPTO Provides Increased Clarity and Predictability in the Patent Eligibility Determination in a Further Boost for Stakeholders and Innovators in Personalized Medicine

USA - July 19 2018 In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed...


FDA’s New Biosimilar Action Plan Represents the Next Step for Improving Drug Competition

USA - July 19 2018 On July 18, 2018, after months of alluding to the various aspects of an upcoming “Biosimilar Action Plan” as another prong within FDA’s broader Drug...

Joanne Hawana.


With its Vanda Pharma and Berkheimer memos, USPTO provides increased clarity around personalized medicine patent eligibility

USA - June 22 2018 In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed...


USPTO Guidance for examiners takes expansive view of Myriad and Prometheus decisions

USA, European Union - March 7 2014 On March 4, 2014, the U.S. Patent and Trademark Office ("USPTO") issued a memorandum to the Patent Examining Corps with guidance for determining the...

Isobel Finnie.


Leahy-Smith America Invents Act what you need to know now

USA - September 16 2011 Far-ranging changes to the U.S. patent system will begin to take effect with President Obama’s signing of the Leahy-Smith America Invents Act (“the Leahy-Smith AIA”)....

David E. Johnson, Ph.D..